Ganesh Gunasekaran, Kalman Bencsath, Vera Hupertz, John J. Fung, Gosta Pettersson, Charles Miller – 7 September 2010 – Liver transplantation is the treatment of choice for many liver diseases in the pediatric population. Complications involving late suprahepatic vena cava obstructions after liver transplantation are not common, but they tend to be more frequently seen in pediatric recipients. When such complications have occurred, approaches involving direct abdominal surgery or interventional radiology guidance have been used with satisfactory results.

María Úbeda, Leticia Muñoz, María‐José Borrero, David Díaz, Rubén Francés, Jorge Monserrat, Margaret Lario, Lourdes Lledó, José Such, Melchor Álvarez‐Mon, Agustín Albillos – 7 September 2010 – Systemic activation of the inflammatory immune system contributes to the progression of cirrhosis with ascites. Immune cells become activated after interacting at the mesenteric lymph nodes (MLNs) with bacteria translocated from the gut, and thereafter reach the bloodstream through recirculation.

Sadahisa Okamoto, Rolf Hörnsten, Konen Obayashi, Priyantha Wijayatunga, Ole B. Suhr – 7 September 2010 – In patients with familial amyloidotic polyneuropathy (FAP), heart complications are prognostic factors for mortality and morbidity after liver transplantation (LT). However, only a few studies have analyzed the development of arrhythmia in transplant patients with FAP. We investigated the development of arrhythmia requiring pacemaker insertion (PMI) in Swedish transplant patients with FAP, and we related the findings to gender, age at disease onset, and survival.

Sandro Rossi, Valentina Ravetta, Laura Rosa, Giorgia Ghittoni, Francesca Torello Viera, Francesco Garbagnati, Enrico Maria Silini, Paolo Dionigi, Fabrizio Calliada, Pietro Quaretti, Carmine Tinelli – 7 September 2010 – In most patients with cirrhosis, successful percutaneous ablation or surgical resection of hepatocellular carcinoma (HCC) is followed by recurrence. Radiofrequency ablation (RFA) has proven effective for treating HCC nodules, but its repeatability in managing recurrences and the impact of this approach on survival has not been evaluated.

Yinghua Tian, Rolf Graf, Ashraf Mohammad El‐Badry, Mickaël Lesurtel, Katarzyna Furrer, Wolfgang Moritz, Pierre‐Alain Clavien – 7 September 2010 – The implantation of grafts below 30% of the normal liver volume is associated with a high risk of failure known as small‐for‐size (SFS) syndrome. Strategies to rescue small grafts may have a dramatic impact on organ shortage. Serotonin is a potent growth factor for the liver. The goal of this study was to determine whether enhanced serotonin signaling could prevent the deleterious effects of SFS syndrome.

Carlos M. Rodriguez‐Ortigosa, Fernando Corrales, Juan F. Medina, Jesús Prieto – 7 September 2010

Lionel Piroth, Christine Larsen, Christine Binquet, Laurent Alric, Isabelle Auperin, Marie‐Laure Chaix, Stéphanie Dominguez, Xavier Duval, Anne Gervais, Jade Ghosn, Elisabeth Delarocque‐Astagneau, Stanislas Pol – 7 September 2010 – Acute hepatitis C continues to be a concern in men who have sex with men (MSM), and its optimal management has yet to be established.

Catherine H. McCrann, James L. Boyer – 7 September 2010

Mei‐Chuan Chen, Chun‐Han Chen, Hsiao‐Ching Chuang, Samuel K. Kulp, Che‐Ming Teng, Ching‐Shih Chen – 7 September 2010 – Histone deacetylase (HDAC) inhibitors exhibit a unique ability to degrade topoisomerase (topo)IIα in hepatocellular carcinoma (HCC) cells, which contrasts with the effect of topoII‐targeted drugs on topoIIβ degradation. This selective degradation might foster novel strategies for HCC treatment in light of the correlation of topoIIα overexpression with the aggressive tumor phenotype and chemoresistance.

Magnus Lindh, Martin Lagging, Gunnar Norkrans, Kristoffer Hellstrand – 7 September 2010